Cipher Pharmaceuticals Inc
TSX:CPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hefei Hengxin Life Science and Technology Co Ltd
SZSE:301501
|
CN |
|
N
|
Novo Nordisk A/S
LSE:0QIU
|
DK |
Cipher Pharmaceuticals Inc
Total Receivables
Cipher Pharmaceuticals Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Total Receivables
$10.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Total Receivables
$2.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-1%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Total Receivables
CA$32.5m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
36%
|
|
|
Cronos Group Inc
TSX:CRON
|
Total Receivables
$57.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Total Receivables
CA$138.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
46%
|
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.
See Also
What is Cipher Pharmaceuticals Inc's Total Receivables?
Total Receivables
10.1m
USD
Based on the financial report for Sep 30, 2025, Cipher Pharmaceuticals Inc's Total Receivables amounts to 10.1m USD.
What is Cipher Pharmaceuticals Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
-3%
Over the last year, the Total Receivables growth was -22%. The average annual Total Receivables growth rates for Cipher Pharmaceuticals Inc have been 18% over the past three years , -3% over the past five years , and -3% over the past ten years .
